Endocrinol Metab.  2024 Dec;39(6):932-945. 10.3803/EnM.2024.2061.

Alterations in Adipose Tissue and Adipokines in Heterozygous APE1/Ref-1 Deficient Mice

• Lee EO
• Jin H
• Kim S
• Joo HK
• Lee YR
• An SY
• Piao S
• Lee KH
• Jeon BH

• KMID: 2562721
• DOI: http://doi.org/10.3803/EnM.2024.2061

Abstract

Background
The role of apurinic/apyrimidinic endonuclease 1/redox factor-1 (APE1/Ref-1) in adipose tissue remains poorly understood. This study investigates adipose tissue dysfunction in heterozygous APE1/Ref-1 deficiency (APE1/Ref-1^+/-) mice, focusing on changes in adipocyte physiology, oxidative stress, adipokine regulation, and adipose tissue distribution.
Methods
APE1/Ref-1 mRNA and protein levels in white adipose tissue (WAT) were measured in APE1/Ref-1^+/- mice, compared to their wild-type (APE1/Ref-1+/+) controls. Oxidative stress was assessed by evaluating reactive oxygen species (ROS) levels. Histological and immunohistochemical analyses were conducted to observe adipocyte size and macrophage infiltration of WAT. Adipokine expression was measured, and micro-magnetic resonance imaging (MRI) was used to quantify abdominal fat volumes.
Results
APE1/Ref-1^+/- mice exhibited significant reductions in APE1/Ref-1 mRNA and protein levels in WAT and liver tissue. These mice also showed elevated ROS levels, suggesting a regulatory role for APE1/Ref-1 in oxidative stress in WAT and liver. Histological and immunohistochemical analyses revealed hypertrophic adipocytes and macrophage infiltration in WAT, while Oil Red O staining demonstrated enhanced ectopic fat deposition in the liver of APE1/Ref-1^+/- mice. These mice also displayed altered adipokine expression, with decreased adiponectin and increased leptin levels in the WAT, along with corresponding alterations in plasma levels. Despite no significant changes in overall body weight, microMRI assessments demonstrated a significant increase in visceral and subcutaneous abdominal fat volumes in APE1/Ref-1^+/- mice.
Conclusion
APE1/Ref-1 is crucial in adipokine regulation and mitigating oxidative stress. These findings suggest its involvement in adipose tissue dysfunction, highlighting its potential impact on abdominal fat distribution and its implications for obesity and oxidative stress-related conditions.

Keyword

Abdominal fat distribution; Adipokine expression; Adipose tissue dysfunction; APE1/Ref-1; Oxidative stress

Figure

• 

  Fig. 1. Generation of heterozygous apurinic/apyrimidinic endonuclase1/redox factor-1 (APE1/Ref-1) deficiency mice. (A) Targeting schema of the APE1/Ref-1 gene deletion with loxP sites flanking exons 2 and 3. Knockout of the APE1/Ref-1 gene was generated via the repair of double-strand breaks using non-homologous end joining. (B) Polymerase chain reaction genotyping for detection of the APE1/Ref-1 in genomic DNA from heterozygous (APE1/Ref-1+/-) mice, wild-type (APE1/Ref-1+/+) mice. The presence of a 1,460 bp band indicates the wild-type allele, while the presence of a 568 bp band confirms the detection of the deleted allele. (C) The body weight of 20-week-old male heterozygous (APE1/Ref-1+/-) mice and wild-type (APE1/Ref-1+/+) mice (n=10). There is no significant (NS) change in body weight observed between both groups. (D) Reduced APE1/Ref-1 mRNA expression in the white adipose tissue (WAT) of APE1/Ref-1+/- mice (n=5). mRNA levels were analyzed with quantitative reverse transcription-polymerase chain reaction as described in the ‘Methods’ section. (E) Western blotting results of APE1/Ref-1 protein expression in WAT. Data presented are representative of three independent experiments. (F) Quantitative analysis for Western blotting of APE1/Ref-1 protein expression in WAT of APE1/Ref-1+/- and APE1/Ref-1+/+ mice (n=9). (G) Western blotting results of APE1/Ref-1 protein expression in liver. (H) Quantitative analysis to measure APE1/Ref-1 protein expression in liver of APE1/Ref-1+/- and APE1/Ref-1+/+ mice (n=6). The data represent the mean±standard error of the mean. Statistical significance is indicated as NS. EcoRI and BamHI means restriction endonuclease enzyme sites. aP<0.001 vs. APE1/Ref-1+/+ mice.

• 

  Fig. 2. Abnormal oxidative stress state in the white adipose tissue (WAT) of heterozygous apurinic/apyrimidinic endonuclase1/redox factor- 1 (APE1/Ref-1)-deficient mice. (A) Increased total reactive oxygen species (ROS) production in WAT of APE1/Ref-1+/- mice (n=5–6). (B) Increased superoxide production in APE1/Ref-1+/- compared to APE1/Ref-1+/+ mice in WAT (n=5–6). (C) Increased total ROS production in APE1/Ref-1+/- compared to APE1/Ref-1+/+ mice (n=5). Total ROS was measured with dichlorofluorescein assay. (D) Increased superoxide production in the liver of APE1/Ref-1+/- mice (n=6). Superoxide production was measured with lucigenin-enhanced chemiluminescence. The data represent the mean±standard error of the mean. RFU, relative fluorescence unit; RLU, relative luminescence unit. aP<0.05 vs. APE1/Ref-1+/+ mice.

• 

  Fig. 3. Adipocyte hypertrophy in white adipose tissue (WAT) and hepatic fat accumulation in heterozygous apurinic/apyrimidinic endonuclase1/ redox factor-1 (APE1/Ref-1)-deficient mice. (A) Low power (4×) and high power (10×) image of hematoxylin and eosin (H&E) staining in WAT from the APE1/Ref-1+/+ mice and APE1/Ref-1+/- mice. Note that APE1/Ref-1+/- mice exhibit larger adipocytes compared to APE1/Ref-1+/+ mice. (B) Mean adipose diameters in WAT of APE1/Ref-1+/- mice and APE1/Ref-1+/+ mice. Mean adipose diameters in WAT of APE1/Ref-1+/- mice are significantly larger than those of APE1/Ref-1+/+ mice, indicating adipose hypertrophy (n=3). (C) Immunohistochemical detection of the macrophage-specific antigen F4/80 in WAT of APE1/Ref-1+/- mice. (D) Quantitative analysis of F4/80 expression in WAT of APE1/Ref-1+/- mice. Macrophage infiltrations are increased in adipose tissue of APE1/Ref-1+/- mice (n=3). (E) Low power (4×) and high power (40×) image H&E staining in liver tissue from APE1/Ref-1+/+ mice and APE1/Ref-1+/- mice. Fat vacuoles are observed in the liver of APE1/Ref-1+/- mice, not in APE1/Ref-1+/+ mice. (F) Quantitative analysis of hepatic steatosis in non-adipose tissue of APE1/Ref- 1+/- mice. Hepatic steatosis was analyzed by histopathological scoring as described in the ‘Methods’ section (n=3). (G) Oil Red O staining for lipid detection in frozen liver tissue sections of APE1/Ref-1+/+ and APE1/Ref-1+/- mice. (H) Quantification of the percentage of increased triglyceride content in liver tissue of APE1/Ref-1+/- mice compared to APE1/Ref-1+/+ mice. The data represent the mean±standard error of the mean (n=3–5). aP<0.05 vs. APE1/Ref-1+/+ mice.

• 

  Fig. 4. Decreased adiponectin in heterozygous apurinic/apyrimidinic endonuclase1/redox factor-1 (APE1/Ref-1)-deficient mice. (A) Decreased mRNA expression of adiponectin in the white adipose tissue (WAT) of APE1/Ref-1+/- mice (n=5). mRNA levels were analyzed with quantitative reverse transcription-polymerase chain reaction as described in the ‘Methods’ section. (B) Representative Western blot analysis of adiponectin protein expression in WAT from three individual mice. (C) Quantitative analysis of adiponectin protein expression in WAT normalized to β-actin showing reduced expression in APE1/Ref-1+/- mice, compared to APE1/Ref-1+/+ mice (n=9). (D) Immunohistochemistry staining of adiponectin showing reduced expression in WAT of APE1/Ref-1+/- mice. (E) Reduced plasma adiponectin levels in APE1/ Ref-1+/- mice compared to APE1/Ref-1+/+ mice (n=6). The data represent the mean±standard error of the mean. aP<0.05; bP<0.01; cP<0.001 vs. APE1/Ref-1+/+ mice.

• 

  Fig. 5. Elevated leptin expression in heterozygous apurinic/apyrimidinic endonuclase1/redox factor-1 (APE1/Ref-1)-deficient mice. (A) Increased leptin mRNA expression in the white adipose tissue (WAT) of APE1/Ref-1+/- mice than in APE1/Ref-1+/+ mice (n=5). mRNA levels were analyzed with quantitative reverse transcription-polymerase chain reaction as described in the ‘Methods’ section. (B) Representative Western blotting results of leptin protein expression in WAT from three individual mice. (C) Quantitative analysis of leptin protein expression in WAT normalized to β-actin showing increased expression in APE1/Ref-1+/- mice, compared to APE1/Ref-1+/+ mice (n=6). (D) Immunohistochemistry staining of leptin showing increased expression in the WAT of APE1/Ref-1+/- mice. (E) Increased leptin levels of plasma in APE1/Ref-1+/- mice compared to APE1/Ref-1+/+ mice (n=4). The data represent the mean±standard error of the mean. aP<0.001 vs. APE1/Ref-1+/+ mice.

• 

  Fig. 6. Quantification of increased abdominal fat area in heterozygous apurinic/apyrimidinic endonuclase1/redox factor-1 (APE1/Ref-1) deficiency mice using micro-magnetic resonance imaging (MRI). (A) Representative microMRI images of coronal sections to determine abdominal localization. The gray box indicates the abdominal analysis area yielding the results in panels C-F. The white line indicates the position of the transverse sectional image that is shown in panel B. (B) Representative transverse sectional image of the abdomen (visceral fat [V], subcutaneous fat [S]). (C) Results of increased visceral fat volume in APE1/Ref-1+/- mice compared to APE1/Ref-1+/+ mice (n=5–6). (D) Thicker abdominal subcutaneous fat volume in APE1/Ref-1+/- mice (n=5–6). (E) APE1/Ref-1+/- mice with greater total abdominal fat, which is the sum of visceral and subcutaneous fat (n=5–6). (F) Average abdominal cross-sectional area between the two groups without difference (n=5–6). Data are presented as mean±standard error of the mean. NS, no significant. aP<0.05 vs. APE1/Ref-1+/+.

• 

Reference

1. Gu X, Wang L, Liu S, Shan T. Adipose tissue adipokines and lipokines: functions and regulatory mechanism in skeletal muscle development and homeostasis. Metabolism. 2023; 139:155379.

2. Bluher M. Adipose tissue dysfunction in obesity. Exp Clin Endocrinol Diabetes. 2009; 117:241–50.

3. Bluher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019; 15:288–98.

4. Bluher M. Adipose tissue dysfunction contributes to obesity related metabolic diseases. Best Pract Res Clin Endocrinol Metab. 2013; 27:163–77.

5. Goossens GH. The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance. Physiol Behav. 2008; 94:206–18.

6. Schwartz MW, Seeley RJ, Zeltser LM, Drewnowski A, Ravussin E, Redman LM, et al. Obesity pathogenesis: an Endocrine Society scientific statement. Endocr Rev. 2017; 38:267–96.

7. Goossens GH, Blaak EE. Adipose tissue dysfunction and impaired metabolic health in human obesity: a matter of oxygen? Front Endocrinol (Lausanne). 2015; 6:55.

8. Castro JP, Grune T, Speckmann B. The two faces of reactive oxygen species (ROS) in adipocyte function and dysfunction. Biol Chem. 2016; 397:709–24.

9. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001; 7:941–6.

10. Nguyen TM. Adiponectin: role in physiology and pathophysiology. Int J Prev Med. 2020; 11:136.

11. Izquierdo AG, Crujeiras AB, Casanueva FF, Carreira MC. Leptin, obesity, and leptin resistance: where are we 25 years later? Nutrients. 2019; 11:2704.

12. Obradovic M, Sudar-Milovanovic E, Soskic S, Essack M, Arya S, Stewart AJ, et al. Leptin and obesity: role and clinical implication. Front Endocrinol (Lausanne). 2021; 12:585887.

13. Dornbush S, Aeddula NR. Physiology, leptin. Treasure Island: StatPearls Publishing;2024. [cited 2024 Sep 4]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK537038.

14. Choi S, Joo HK, Jeon BH. Dynamic regulation of APE1/ Ref-1 as a therapeutic target protein. Chonnam Med J. 2016; 52:75–80.

15. Tell G, Quadrifoglio F, Tiribelli C, Kelley MR. The many functions of APE1/Ref-1: not only a DNA repair enzyme. Antioxid Redox Signal. 2009; 11:601–20.

16. Lee EO, Joo HK, Lee YR, Kim S, Lee KH, Lee SD, et al. APE1/Ref-1 inhibits adipogenic transcription factors during adipocyte differentiation in 3T3-L1 cells. Int J Mol Sci. 2023; 24:3251.

17. Domenis R, Bergamin N, Gianfranceschi G, Vascotto C, Romanello M, Rigo S, et al. The redox function of APE1 is involved in the differentiation process of stem cells toward a neuronal cell fate. PLoS One. 2014; 9:e89232.

18. Guzik TJ, Channon KM. Measurement of vascular reactive oxygen species production by chemiluminescence. Methods Mol Med. 2005; 108:73–89.

19. Joo HK, Lee YR, Lee EO, Kim S, Jin H, Kim S, et al. Protective role of dietary capsanthin in a mouse model of nonalcoholic fatty liver disease. J Med Food. 2021; 24:635–44.

20. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41:1313–21.

21. Poulain L, Mathieu H, Thomas A, Borel AL, Remy C, Levy P, et al. Intermittent hypoxia-induced insulin resistance is associated with alterations in white fat distribution. Sci Rep. 2017; 7:11180.

22. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004; 114:1752–61.

23. Anderson EJ, Lustig ME, Boyle KE, Woodlief TL, Kane DA, Lin CT, et al. Mitochondrial H2O₂ emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans. J Clin Invest. 2009; 119:573–81.

24. Jeon BH, Irani K. APE1/Ref-1: versatility in progress. Antioxid Redox Signal. 2009; 11:571–4.

25. Gordon S, Hamann J, Lin HH, Stacey M. F4/80 and the related adhesion-GPCRs. Eur J Immunol. 2011; 41:2472–6.

26. Lee HM, Jeon BH, Won KJ, Lee CK, Park TK, Choi WS, et al. Gene transfer of redox factor-1 inhibits neointimal formation: involvement of platelet-derived growth factor-beta receptor signaling via the inhibition of the reactive oxygen species-mediated Syk pathway. Circ Res. 2009; 104:219–27.

27. den Hartog G, Chattopadhyay R, Ablack A, Hall EH, Butcher LD, Bhattacharyya A, et al. Regulation of Rac1 and reactive oxygen species production in response to infection of gastrointestinal epithelia. PLoS Pathog. 2016; 12:e1005382.

28. Du Y, Zhou Y, Yan X, Pan F, He L, Guo Z, et al. APE1 inhibition enhances ferroptotic cell death and contributes to hepatocellular carcinoma therapy. Cell Death Differ. 2024; 31:431–46.

29. Magherini F, Fiaschi T, Marzocchini R, Mannelli M, Gamberi T, Modesti PA, et al. Oxidative stress in exercise training: the involvement of inflammation and peripheral signals. Free Radic Res. 2019; 53:1155–65.

30. Naryzhnaya NV, Koshelskaya OA, Kologrivova IV, Suslova TE, Kharitonova OA, Andreev SL, et al. Production of reactive oxygen species by epicardial adipocytes is associated with an increase in postprandial glycemia, postprandial insulin, and a decrease in serum adiponectin in patients with severe coronary atherosclerosis. Biomedicines. 2022; 10:2054.

31. Yang R, Barouch LA. Leptin signaling and obesity: cardiovascular consequences. Circ Res. 2007; 101:545–59.

32. de Villiers D, Potgieter M, Ambele MA, Adam L, Durandt C, Pepper MS. The role of reactive oxygen species in adipogenic differentiation. Adv Exp Med Biol. 2018; 1083:125–44.

33. Ozaki M, Suzuki S, Irani K. Redox factor-1/APE suppresses oxidative stress by inhibiting the rac1 GTPase. FASEB J. 2002; 16:889–90.

34. Joo HK, Lee YR, Park MS, Choi S, Park K, Lee SK, et al. Mitochondrial APE1/Ref-1 suppressed protein kinase C-induced mitochondrial dysfunction in mouse endothelial cells. Mitochondrion. 2014; 17:42–9.

35. Lee KM, Lee EO, Lee YR, Joo HK, Park MS, Kim CS, et al. APE1/Ref-1 inhibits phosphate-induced calcification and osteoblastic phenotype changes in vascular smooth muscle cells. Int J Mol Sci. 2017; 18:2053.

36. Gurusamy N, Mukherjee S, Lekli I, Bearzi C, Bardelli S, Das DK. Inhibition of ref-1 stimulates the production of reactive oxygen species and induces differentiation in adult cardiac stem cells. Antioxid Redox Signal. 2009; 11:589–600.

37. Cichoz-Lach H, Michalak A. Oxidative stress as a crucial factor in liver diseases. World J Gastroenterol. 2014; 20:8082–91.

38. Chen Z, Tian R, She Z, Cai J, Li H. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. Free Radic Biol Med. 2020; 152:116–41.

39. Hall KD, Heymsfield SB, Kemnitz JW, Klein S, Schoeller DA, Speakman JR. Energy balance and its components: implications for body weight regulation. Am J Clin Nutr. 2012; 95:989–94.

40. Gruzdeva O, Borodkina D, Uchasova E, Dyleva Y, Barbarash O. Leptin resistance: underlying mechanisms and diagnosis. Diabetes Metab Syndr Obes. 2019; 12:191–8.

41. Achari AE, Jain SK. Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction. Int J Mol Sci. 2017; 18:1321.